Lipella Pharmaceuticals: 363 Sale of Biotech IP After Nasdaq Delisting
Lipella Pharmaceuticals filed chapter 11 to pursue a 363 sale of its liposomal drug delivery IP after Nasdaq delisting and cash runway exhaustion.
In this article
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on liposomal drug delivery, filed a voluntary chapter 11 petition on March 30, 2026, in the U.S. Bankruptcy Court for the Western District of Pennsylvania. The company intends to pursue a Section 363 sale. Lipella, which completed its IPO in December 2022 and was delisted from Nasdaq in June 2025 for listing rule violations, reported $536,357 in revenue for fiscal year 2024 against a net loss of $5.02 million. The stock traded at approximately $0.15 per share at the time of filing, giving the company a market capitalization under $700,000.
| Debtor(s) | Lipella Pharmaceuticals Inc. |
| Court | U.S. Bankruptcy Court, Western District of Pennsylvania |
| Petition Date | March 30, 2026 |
| Estimated Assets | $1M-$10M |
| Estimated Liabilities | $1M-$10M |
| Ticker | LIPO (OTC Markets; formerly Nasdaq) |
Company Background
Lipella Pharmaceuticals was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. The company develops drugs by reformulating active agents in existing generics using a proprietary liposomal delivery technology that targets mucosal tissues. Co-founders Jonathan Kaufman, PhD (CEO) and Michael Chancellor, MD (CMO) built the company around tacrolimus-based formulations for conditions with no approved drug therapies.
The company's pipeline included LP-10, a liposomal tacrolimus for hemorrhagic cystitis with FDA Orphan Drug Designation, and LP-310, a liposomal tacrolimus oral rinse for oral lichen planus. LP-310 completed a Phase 2a trial across 27 patients in February 2025, and the FDA granted Expanded Access Program approval for the drug. The company also held U.S. Patent No. 12,138,345 for its core liposomal delivery platform, issued November 2024.
Lipella completed its IPO on the Nasdaq Capital Market in December 2022. The company employed approximately seven people and maintained a sterile manufacturing facility in Pittsburgh for clinical supplies.
Causes of Distress
Lipella was a pre-revenue clinical-stage company with sustained annual losses exceeding $5 million. For fiscal year 2024, the company reported $536,357 in revenue and a net loss of $5.02 million. Cash and cash equivalents stood at $2.2 million as of December 31, 2024.
The company raised approximately $5.9 million through a private placement conducted between December 2024 and March 2025, with Spartan Capital Securities as exclusive placement agent. The terms of that raise triggered Nasdaq delisting. On June 20, 2025, Nasdaq delisted Lipella for violations of Listing Rules 5100, 5635, and 5640, related to the issuance of Series C voting convertible preferred stock and warrants to Spartan Capital during the private placement. The stock fell 30% on the delisting announcement and moved to OTC Markets.
The company had previously executed a 1-for-8 reverse stock split in November 2024 to regain Nasdaq bid price compliance. By March 2026, shares traded at an all-time low of approximately $0.15, representing a market capitalization under $700,000.
363 Sale Process
Lipella stated it intends to pursue a 363 sale process to maximize creditor recoveries. The company's principal assets include its intellectual property portfolio, the LP-310 and LP-10 clinical programs with associated FDA designations, U.S. Patent No. 12,138,345 covering the liposomal delivery platform, clinical data, and the Pittsburgh manufacturing facility.
No stalking horse bidder, sale timeline, or bidding procedures have been disclosed. The company stated it expects to seek first-day relief to maintain operations during the sale process.
Key Timeline
| Date | Event |
|---|---|
| 2005 | Lipella Pharmaceuticals incorporated |
| December 2022 | IPO on Nasdaq Capital Market |
| November 2024 | 1-for-8 reverse stock split; U.S. Patent No. 12,138,345 issued |
| December 2024 - March 2025 | $5.9M private placement (Spartan Capital) |
| February 2025 | LP-310 Phase 2a results; FDA Expanded Access approval |
| June 20, 2025 | Nasdaq delists Lipella for listing rule violations |
| March 2026 | Stock hits all-time low of ~$0.15/share |
| March 30, 2026 | chapter 11 petition filed; 363 sale process announced |
Frequently Asked Questions
Why did Lipella file for bankruptcy?
Lipella was a pre-revenue clinical-stage company that exhausted its cash runway. Annual losses exceeded $5 million, and the June 2025 Nasdaq delisting removed access to public capital markets. The stock declined to $0.15 per share, leaving the company with a market capitalization under $700,000.
What is being sold?
Lipella intends to sell its assets through a court-supervised Section 363 process. Key assets include the LP-310 and LP-10 drug candidates, associated FDA Orphan Drug and Expanded Access designations, U.S. Patent No. 12,138,345 for its liposomal delivery platform, clinical trial data, and manufacturing equipment.
What happens to shareholders?
The company warned that trading in LIPO common stock during chapter 11 proceedings is "highly speculative" and may not reflect eventual recoveries. With a sub-$700,000 market capitalization at filing, equity recovery is uncertain.
For more coverage of restructuring cases, explore additional case coverage on ElevenFlo.
This article was researched and written with AI assistance, using court filings, public records, and news sources. AI-generated content can contain errors. Verify all information against primary sources before relying on it. This is not legal or financial advice. Read our full disclaimer.